Literature DB >> 36222958

Mahonia Alkaloids (MA) Ameliorate Depression Induced Gap Junction Dysfunction by miR-205/Cx43 Axis.

Junhui He1, Dongmei Li1, Jie Wei1, Sheng Wang2, Shifeng Chu3, Zhao Zhang3, Fei He1, Dongmei Wei1, Yi Li1, Jiaxiu Xie1, Kedao Lai1, Naihong Chen4, Guining Wei5,6.   

Abstract

Depression has become an important disease threatening human health. In recent years, the efficacy of Traditional Chinese Medicine (TCM) in treating the disease has become increasingly prominent, so it is meaningful to find new antidepressant TCM. Mahonia fortune (Lindl.) Fedde is a primary drug in traditional formulas for the treatment of depression, and alkaloids are the main components of it. However, the detailed mechanism of Mahonia alkaloids (MA) on depression remains unclear. This study aimed to investigate the effect of MA on gap junction function in depression via the miR-205/Cx43 axis. The antidepressant effects of MA were observed by a rat model of reserpine-induced depression and a model of corticosterone (CORT)-induced astrocytes. The concentrations of neurotransmitters were measured by ELISA, the expression of Connexin 43 (Cx43) protein was measured by Immunohistochemistry and western-blot, brain derived neurotrophic factor (BDNF), cAMP-response element binding protein (CREB) proteins were measured by western-blot, the pathological changes of prefrontal cortex were observed by hematoxylin-eosin (H&E) staining. Luciferase reporter assay was performed to verify the binding of miR-205 and Cx43. The regulation effect of Cx43 on CREB was verified by interference experiment. Gap junction dysfunction was detected by fluorescent yellow staining. The results confirmed that MA remarkably decreased miR-205 expression and increased Cx43, BDNF, CREB expression in depression rat and CORT-induced astrocytes. In addition, after overexpression of miR-205 in vitro, the decreased expression of Cx43, BDNF and CREB could be reversed by MA. Moreover, after interfering with Cx43, the decreased expression of CREB and BDNF could be reversed by MA. Thus, MA may ameliorate depressive behavior through CREB/BDNF pathway regulated by miR-205/Cx43 axis.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  BDNF; CREB; Cx43; Depression; Mahonia alkaloids

Year:  2022        PMID: 36222958     DOI: 10.1007/s11064-022-03761-3

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   4.414


  33 in total

Review 1.  MicroRNAs: genomics, biogenesis, mechanism, and function.

Authors:  David P Bartel
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

Review 2.  MicroRNAs in neural development: from master regulators to fine-tuners.

Authors:  Marek Rajman; Gerhard Schratt
Journal:  Development       Date:  2017-07-01       Impact factor: 6.868

Review 3.  Dysregulation of miRNA and its potential therapeutic application in schizophrenia.

Authors:  Ting Cao; Xue-Chu Zhen
Journal:  CNS Neurosci Ther       Date:  2018-03-12       Impact factor: 5.243

4.  Epidemiology of Major Depressive Disorder Disability in the US Military: FY 2007-2012.

Authors:  Elizabeth R Packnett; Hoda Elmasry; Christine F Toolin; David N Cowan; Michael R Boivin
Journal:  J Nerv Ment Dis       Date:  2017-09       Impact factor: 2.254

Review 5.  Many roads to maturity: microRNA biogenesis pathways and their regulation.

Authors:  Julia Winter; Stephanie Jung; Sarina Keller; Richard I Gregory; Sven Diederichs
Journal:  Nat Cell Biol       Date:  2009-03       Impact factor: 28.824

6.  Connexin 43: A novel ginsenoside Rg1-sensitive target in a rat model of depression.

Authors:  Cong-Yuan Xia; Zhen-Zhen Wang; Hui-Qin Wang; Si-Yu Ren; Yu-Xia Lou; Can Jin; Tian-Ge Qu; Si-Tong Feng; Yi Zhang; Shi-Feng Chu; Nai-Hong Chen
Journal:  Neuropharmacology       Date:  2020-03-05       Impact factor: 5.250

7.  Novel antidepressant mechanism of ginsenoside Rg1: Regulating biosynthesis and degradation of connexin43.

Authors:  Hui-Qin Wang; Song-Wei Yang; Yan Gao; Ying-Jiao Liu; Xun Li; Qi-Di Ai; Mei-Yu Lin; Yan-Tao Yang; Qi Zeng; Yi Zhang; Zhen-Zhen Wang; Nai-Hong Chen
Journal:  J Ethnopharmacol       Date:  2021-06-01       Impact factor: 4.360

8.  Treatment resistant depression or dementia: a case report.

Authors:  Zhongyong Shi; Shifu Xiao; Xia Li
Journal:  Shanghai Arch Psychiatry       Date:  2016-04-25

Review 9.  MicroRNAs in Neurocognitive Dysfunctions: New Molecular Targets for Pharmacological Treatments?

Authors:  Wissem Deraredj Nadim; Viorel Simion; Helene Benedetti; Chantal Pichon; Patrick Baril; Severine Morisset-Lopez
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.